{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:21:37Z","timestamp":1761974497538,"version":"3.37.3"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T00:00:00Z","timestamp":1708646400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T00:00:00Z","timestamp":1708646400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Schleswig-Holstein - Campus Kiel"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>To summarize the radiotherapy-relevant statements of the 18th St.\u00a0Gallen Breast Cancer Consensus Conference and interpret the findings in light of German guideline recommendations.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Statements and voting results from the 18th St.\u00a0Gallen International Breast Cancer Consensus Conference were collected and analyzed according to their relevance for the radiation oncology community. The voting results were discussed in two hybrid meetings among the authors of this manuscript on March 18 and 19, 2023, in light of the German S3 guideline and the 2023 version of the <jats:italic>Arbeitsgemeinschaft Gyn\u00e4kologische Onkologie<\/jats:italic> (AGO) guidelines.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results and conclusion<\/jats:title>\n                <jats:p>There was a\u00a0high level of agreement between the radiotherapy-related statements of the 18th St.\u00a0Gallen International Breast Cancer Consensus Conference and the German S3 and AGO guidelines. Discrepancies include the impact of number of lymph node metastases for the indication for postmastectomy radiotherapy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00066-024-02209-7","type":"journal-article","created":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T13:02:29Z","timestamp":1708693349000},"page":"461-467","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Radiotherapy statements of the 18th St.\u00a0Gallen International Breast Cancer Consensus Conference\u2014a\u00a0German expert perspective"],"prefix":"10.1007","volume":"200","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8811-5416","authenticated-orcid":false,"given":"David","family":"Krug","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maggie","family":"Banys-Paluchowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara Y.","family":"Brucker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carsten","family":"Denkert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nina","family":"Ditsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter A.","family":"Fasching","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renate","family":"Haidinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia","family":"Harbeck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f6rg","family":"Heil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Huober","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Jackisch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Janni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans-Christian","family":"Kolberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sibylle","family":"Loibl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"L\u00fcftner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marion","family":"van Mackelenbergh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia C.","family":"Radosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toralf","family":"Reimer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manfred","family":"Welslau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"W\u00fcrstlein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Untch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilfried","family":"Budach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,2,23]]},"reference":[{"key":"2209_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.08.017","author":"G Curigliano","year":"2023","unstructured":"Curigliano\u00a0G, Burstein\u00a0HJ, Gnant\u00a0M et\u00a0al (2023) Understanding breast cancer complexity to improve patient outcomes: the St. Gallen international consensus conference for the primary therapy of individuals with early breast cancer 2023. Ann Oncol. https:\/\/doi.org\/10.1016\/j.annonc.2023.08.017","journal-title":"Ann Oncol"},{"key":"2209_CR2","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1055\/a-2121-2495","volume":"83","author":"M Untch","year":"2023","unstructured":"Untch\u00a0M, Banys-Paluchowski\u00a0M, Brucker\u00a0SY et\u00a0al (2023) Treatment of early breast cancer. Geburtshilfe Frauenheilkd 83:1102\u20131116. https:\/\/doi.org\/10.1055\/a-2121-2495","journal-title":"Geburtshilfe Frauenheilkd"},{"key":"2209_CR3","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1055\/a-0646-4630","volume":"78","author":"A W\u00f6ckel","year":"2018","unstructured":"W\u00f6ckel\u00a0A, Festl\u00a0J, St\u00fcber\u00a0T et\u00a0al (2018) Interdisciplinary screening, diagnosis, therapy and follow-up of breast cancer. Guideline of the DGGG and the DKG (S3-level, AWMF registry number 032\/045OL, december 2017)\u2014part 2 with recommendations for the therapy of primary, recurrent and advanced breast cancer. Geburtshilfe Frauenheilkd 78:1056\u20131088. https:\/\/doi.org\/10.1055\/a-0646-4630","journal-title":"Geburtshilfe Frauenheilkd"},{"key":"2209_CR4","doi-asserted-by":"publisher","DOI":"10.1159\/000531578","author":"T-W Park-Simon","year":"2023","unstructured":"Park-Simon\u00a0T\u2011W, M\u00fcller\u00a0V, Jackisch\u00a0C et\u00a0al (2023) AGO recommendations for the diagnosis and treatment of patients with early breast cancer (EBC): update 2023. Breast Care. https:\/\/doi.org\/10.1159\/000531578","journal-title":"Breast Care"},{"key":"2209_CR5","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1159\/000531579","volume":"18","author":"M Thill","year":"2023","unstructured":"Thill\u00a0M, Kolberg-Liedtke\u00a0C, Albert\u00a0U\u2011S et\u00a0al (2023) AGO recommendations for the diagnosis and treatment of patients with locally advanced and metastatic breast cancer: update 2023. Breast Care 18:305\u2013314. https:\/\/doi.org\/10.1159\/000531579","journal-title":"Breast Care"},{"key":"2209_CR6","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1159\/000531578","volume":"18","author":"T-W Park-Simon","year":"2023","unstructured":"Park-Simon\u00a0T\u2011W, M\u00fcller\u00a0V, Jackisch\u00a0C et\u00a0al (2023) Arbeitsgemeinschaft Gyn\u00e4kologische Onkologie recommendations for the diagnosis and treatment of patients with early breast cancer: update 2023. Breast Care 18:288\u2013304. https:\/\/doi.org\/10.1159\/000531578","journal-title":"Breast Care"},{"key":"2209_CR7","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1093\/jncimonographs\/lgq039","volume":"2010","author":"EBCTCG","year":"2010","unstructured":"EBCTCG (2010) Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. JNCI Monographs 2010:162\u2013177. https:\/\/doi.org\/10.1093\/jncimonographs\/lgq039","journal-title":"JNCI Monographs"},{"key":"2209_CR8","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/s0140-6736(22)01246-6","volume":"400","author":"BH Chua","year":"2022","unstructured":"Chua\u00a0BH, Link\u00a0EK, Kunkler\u00a0IH et\u00a0al (2022) Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast (BIG 3\u201307\/TROG 07.01): a\u00a0randomised, factorial, multicentre, open-label, phase\u00a03 study. Lancet 400:431\u2013440. https:\/\/doi.org\/10.1016\/s0140-6736(22)01246-6","journal-title":"Lancet"},{"key":"2209_CR9","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/s0140-6736(15)00471-7","volume":"387","author":"V Strnad","year":"2016","unstructured":"Strnad\u00a0V, Ott\u00a0OJ, Hildebrandt\u00a0G et\u00a0al (2016) 5\u2011year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a\u00a0randomised, phase\u00a03, non-inferiority trial. Lancet 387:229\u2013238. https:\/\/doi.org\/10.1016\/s0140-6736(15)00471-7","journal-title":"Lancet"},{"key":"2209_CR10","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1016\/s0140-6736(19)32514-0","volume":"394","author":"FA Vicini","year":"2019","unstructured":"Vicini\u00a0FA, Cecchini\u00a0RS, White\u00a0JR et\u00a0al (2019) Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a\u00a0randomised, phase\u00a03, equivalence trial. Lancet 394:2155\u20132164. https:\/\/doi.org\/10.1016\/s0140-6736(19)32514-0","journal-title":"Lancet"},{"key":"2209_CR11","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1016\/s0140-6736(19)32515-2","volume":"394","author":"TJ Whelan","year":"2019","unstructured":"Whelan\u00a0TJ, Julian\u00a0JA, Berrang\u00a0TS et\u00a0al (2019) External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a\u00a0randomised controlled trial. Lancet 394:2165\u20132172. https:\/\/doi.org\/10.1016\/s0140-6736(19)32515-2","journal-title":"Lancet"},{"key":"2209_CR12","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1245\/s10434-013-2918-5","volume":"20","author":"JM Cloyd","year":"2013","unstructured":"Cloyd\u00a0JM, Hernandez-Boussard\u00a0T, Wapnir\u00a0IL (2013) Outcomes of partial mastectomy in male breast cancer patients: analysis of SEER, 1983\u20132009. Ann Surg Oncol 20:1545\u20131550. https:\/\/doi.org\/10.1245\/s10434-013-2918-5","journal-title":"Ann Surg Oncol"},{"key":"2209_CR13","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.ijrobp.2013.07.016","volume":"87","author":"EC Fields","year":"2013","unstructured":"Fields\u00a0EC, DeWitt\u00a0P, Fisher\u00a0CM, Rabinovitch\u00a0R (2013) Management of male breast cancer in the United States: a\u00a0surveillance, epidemiology and end results analysis. Int J Radiat Oncol Biol Phys 87:747\u2013752. https:\/\/doi.org\/10.1016\/j.ijrobp.2013.07.016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2209_CR14","doi-asserted-by":"publisher","first-page":"e997","DOI":"10.1016\/j.clbc.2018.06.013","volume":"18","author":"N Liu","year":"2018","unstructured":"Liu\u00a0N, Johnson\u00a0KJ, Ma\u00a0CX (2018) Male breast cancer: an updated surveillance, epidemiology, and end results data analysis. Clin Breast Cancer 18:e997\u2013e1002. https:\/\/doi.org\/10.1016\/j.clbc.2018.06.013","journal-title":"Clin Breast Cancer"},{"key":"2209_CR15","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1016\/s1470-2045(21)00539-8","volume":"23","author":"I Meattini","year":"2022","unstructured":"Meattini\u00a0I, Becherini\u00a0C, Boersma\u00a0L et\u00a0al (2022) European society for radiotherapy and oncology advisory committee in radiation oncology practice consensus recommendations on patient selection and dose and fractionation for external beam radiotherapy in early breast cancer. Lancet Oncol 23:e21\u2013e31. https:\/\/doi.org\/10.1016\/s1470-2045(21)00539-8","journal-title":"Lancet Oncol"},{"key":"2209_CR16","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s00066-020-01744-3","volume":"197","author":"D Krug","year":"2021","unstructured":"Krug\u00a0D, Baumann\u00a0R, Combs\u00a0SE et\u00a0al (2021) Moderate hypofractionation remains the standard of care for whole-breast radiotherapy in breast cancer: considerations regarding FAST and FAST-forward. Strahlenther Onkol 197:269\u2013280. https:\/\/doi.org\/10.1007\/s00066-020-01744-3","journal-title":"Strahlenther Onkol"},{"key":"2209_CR17","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1056\/nejmoa2207586","volume":"388","author":"IH Kunkler","year":"2023","unstructured":"Kunkler\u00a0IH, Williams\u00a0LJ, Jack\u00a0WJL et\u00a0al (2023) Breast-conserving surgery with or without irradiation in early breast cancer. N\u00a0Engl J Med 388:585\u2013594. https:\/\/doi.org\/10.1056\/nejmoa2207586","journal-title":"N Engl J Med"},{"key":"2209_CR18","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ejca.2019.11.024","volume":"127","author":"G Fastner","year":"2020","unstructured":"Fastner\u00a0G, Sedlmayer\u00a0F, Widder\u00a0J et\u00a0al (2020) Endocrine therapy with or without whole breast irradiation in low-risk breast cancer patients after breast-conserving surgery: 10-year results of the Austrian breast and colorectal cancer study group 8A trial. Eur J Cancer 127:12\u201320. https:\/\/doi.org\/10.1016\/j.ejca.2019.11.024","journal-title":"Eur J Cancer"},{"key":"2209_CR19","doi-asserted-by":"publisher","first-page":"5319","DOI":"10.1200\/jco.2009.21.8560","volume":"27","author":"LL Hughes","year":"2009","unstructured":"Hughes\u00a0LL, Wang\u00a0M, Page\u00a0DL et\u00a0al (2009) Local excision alone without irradiation for ductal carcinoma in situ of the breast: a\u00a0trial of the eastern cooperative oncology group. J\u00a0Clin Oncol 27:5319\u20135324. https:\/\/doi.org\/10.1200\/jco.2009.21.8560","journal-title":"J. Clin. Oncol."},{"key":"2209_CR20","unstructured":"Eierstockkrebs DKFB (2022) Konsensusempfehlungen Stand 2022. https:\/\/webstatic.uk-koeln.de\/im\/dwn\/pboxx-pixelboxx-249678\/klin-konsensus-2022-atm.pdf. Accessed 25 Nov 2023"},{"key":"2209_CR21","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1038\/s41431-020-0638-4","volume":"28","author":"T Frebourg","year":"2020","unstructured":"Frebourg\u00a0T, Lagercrantz\u00a0SB, Oliveira\u00a0C et\u00a0al (2020) Guidelines for the Li\u2013Fraumeni and heritable TP53-related cancer syndromes. Eur J Hum Genet 28:1379\u20131386. https:\/\/doi.org\/10.1038\/s41431-020-0638-4","journal-title":"Eur J Hum Genet"},{"key":"2209_CR22","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1055\/a-1904-6231","volume":"82","author":"M Banys-Paluchowski","year":"2022","unstructured":"Banys-Paluchowski\u00a0M, Thill\u00a0M, K\u00fchn\u00a0T et\u00a0al (2022) AGO recommendations for the surgical therapy of breast cancer: update 2022. Geburtshilfe Frauenheilkd 82:1031\u20131043. https:\/\/doi.org\/10.1055\/a-1904-6231","journal-title":"Geburtshilfe Frauenheilkd"}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-024-02209-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00066-024-02209-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-024-02209-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T11:03:05Z","timestamp":1716375785000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00066-024-02209-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,23]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["2209"],"URL":"https:\/\/doi.org\/10.1007\/s00066-024-02209-7","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"type":"print","value":"0179-7158"},{"type":"electronic","value":"1439-099X"}],"subject":[],"published":{"date-parts":[[2024,2,23]]},"assertion":[{"value":"24 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.\u00a0Krug received remuneration from Merck Sharp & Dohme, med update, onkowissen, Astra Zeneca, Gilead, and Pfizer, as well as research support from Merck KGaA. M.\u00a0Banys-Paluchowski received remuneration from Roche, Novartis, Pfizer, pfm, Eli Lilly, Onkowissen, Seagen, AstraZeneca, Eisai, Amgen, Samsung, Canon, MSD, GSK, Daiichi Sankyo, Gilead, Sirius Pintuition, Pierre Fabre, ExactSciences, Syantra, and Stemline, and study support from EndoMag, Mammotome, Merit Medical, Gilead, Hologic, ExactSciences, and Sirius Medical. S.Y.\u00a0Brucker received remuneration from AstraZeneca, Roche, Novartis, Medtronic, Sanofi, Lilly, MSD, and Hologic. C.\u00a0Denkert received remuneration from Novartis, Roche, MSD Oncology, Daiichi Sankyo, AstraZeneca, Merck, and Molecular Health, and study support from the European Commission, German Cancer Aid, BMBF, GBG, Myriad, and Roche; he is involved in patents for digital pathology (VMscope digital pathology software) and biomarker signatures (patents WO2015114146A1 and WO2010076322A1). N.\u00a0Ditsch received remuneration from Gilead, MSD, Novartis, Pfizer, Roche, Seagen, AstraZeneca, Exact Sciences, Pierre-Fabre, I\u2011Med-Institute, Merit-Medical, pfm medical, Lilly, Aurikamed, Clinsol, and Onkowissen. P.A.\u00a0Fasching received grants from Biontech, Pfizer, and Cepheid, and remuneration from Novartis, Pfizer, Daiichi Sankyo, Astra-Zeneca, Esai, Merck Sharp & Dohme, Lilly, Pierre Fabre, SeaGen, Roche, Agendia, Sanofi Aventis, Gilead, Mylan, and Menarini. N.\u00a0Harbeck received remuneration from Amgen, Astra-Zeneca, Daiichi Sankyo, Gilead, Lilly, MSD, Novartis, Pierre Fabre, Pfizer, Roche, Sandoz, Sanofi, Seagen, Viatris, and Zuelligpharma. J.\u00a0Huober received research funding from Lilly, honoraria from Lilly, Novartis, Roche, Pfizer, AstraZeneca, Seagen, Gilead, and Daiichi, consulting fees from Lilly, Novartis, Roche, Pfizer, AstraZeneca, Gilead, and Daiichi, and travel expenses from Roche, Novartis, Daiichi, and Gilead. C.\u00a0Jackisch received remuneration from Astra Zeneca, Lilly, Celgene, MSD, Eisai, Novartis, Pfizer, Gilead, Daiichi Sankyo, Medupdate, Streamed Up, and Roche, and research support from Exact Sciences. W.\u00a0Janni received remuneration from AstraZeneca, Celgene, Chugai, Daiichi Sankyo, Eisai, ExactScience, GSK, Janssen, Lilly, Menarini, MSD, Novartis, Sanofi-Aventis, Roche, Pfizer, Seagen, Gilead, and Inivata. H.-C.\u00a0Kolberg received remuneration from Pfizer, Novartis, Seagen, Roche, Genomic Health\/Exact Sciences, Amgen, AstraZeneca, Riemser, Carl Zeiss Meditec, Teva, Theraclion, Janssen-Cilag, GSK, LIV Pharma, Lilly, SurgVision, Onkowissen, Gilead, Daiichi Sankyo, and MSD, as well as travel support from Carl Zeiss Meditec, LIV Pharma, Novartis, Amgen, Pfizer, Daiichi Sankyo, Tesaro, Gilead, and Menarini Stemline, and owns shares in Theraclion SA. S.\u00a0Loibl did not receive any remuneration. The following companies granted support and remuneration to the GBG: Abbvie, Amgen, AZ, Celgene\/BMS, Daiichi Sankyo, Gilead, GSK, Incyte, Lilly, MSD, Merck KG, Medupdate, Streamed Up, Novartis, Olema, Pfizer; Relay, Sanofi, Seagen, and Roche. D.\u00a0L\u00fcftner received remuneration from Amgen, Astra Zeneca, Celgene, Daiichi Sankyo, Eli Lilly, Gilead, GSK, high5md, Loreal, Novartis, onkowissen, Pfizer, Roche, and Teva. M.\u00a0van Mackelenbergh received remuneration from Amgen, AstraZeneca, Daiichi Sankyo, GenomicHealth, Gilead, GSK, Lilly, Molecular Health, MSD, Mylan, Novartis, Pfizer, Pierre-Fabre, Roche, and Seagen, and travel fees from Daiichi Sankyo, Gilead, and Lilly. J.C.\u00a0Radosa received remuneration from Pfizer, Eisai, MSD, Medac GmbH, Roche, Novartis, Gedeon Richter, Lilly, Pierre Fabre, Daiichi Sankyo, Seagen, and Theramex. T.\u00a0Reimer received remuneration from AstraZeneca, Daiichi Sankyo, Eli Lilly, Gilead, Myriad, Novartis, Pfizer, and Roche. M.\u00a0Welslau received remuneration from Amgen, Astellas, AstraZeneca, Celgene, Gilead, Hexal, Janssen, Lilly, Novartis, Roche, and Sanofi, and has consulted and reviewed for Amgen, Bristol-Myers Squibb, Celgene, Gilead, Hexal, Janssen, Lilly, Medac, Novartis, Roche, Sanofi, and AstraZeneca. R.\u00a0W\u00fcrstlein received remuneration from Agendia, Amgen, Aristo, Astra Zeneca, Celgene, Clovis Oncology, Daiichi Sankyo, Eisai, Exact Sciences, Gilead, GlaxoSmithKline, Hexal, Lilly, Medstrom Medical, MSD, Mundipharma, Mylan, Nanostring, Novartis, Odonate, Paxman, Palleos, Pfizer, Pierre Fabre, PINK, PumaBiotechnology, Riemser, Roche, Sandoz\/Hexal, Sanofi Genzyme, Seattle Genetics\/Seagen, Stemline, Tesaro Bio, Teva, Veracyte, Viatris, FOMF, Aurikamed, Clinsol, Pomme Med, medconcept, and MCI. M.\u00a0Untch: All remuneration to the employer (advisory boards and travel support): Amgen, AstraZeneca, Daiichi Sankyo, Eisai, Lilly, MSD Merck, Myriad Genetics, Pfizer, Roche, Pierre Fabre, Novartis, Seagen, Gilead, and Stemline. W.\u00a0Budach received remuneration from Merck, BMS, J\u00f6rg Eickeler Veranstaltungen, and medpublico. R.\u00a0Haidinger and J.\u00a0Heil declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}